Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials

BACKGROUND: Pre-clinical evidence shows that fixed dose rate (FDR) infusion of gemcitabine could optimize plasma concentration of gemcitabine, while the clinical efficacy and toxicity of FDR infusion of gemcitabine in advanced pancreatic carcinoma has not been systematically investigated. Thus, this...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Jiqing, Yuan, Jing, Lu, Laichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251942/
https://www.ncbi.nlm.nih.gov/pubmed/25421173
http://dx.doi.org/10.1186/s13000-014-0214-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251942/
https://www.ncbi.nlm.nih.gov/pubmed/25421173
http://dx.doi.org/10.1186/s13000-014-0214-8

Ejemplares similares